Therapeutic approaches include initial symptomatic treatments, such as muscle relaxants [first-line treatment involves the use of GABA A receptor agonists (e.g., benzodiazepines) and second-line treatment involves GABA B receptor agonists (e.g., baclofen)] and immunomodulatory therapy for refractory or severe SPS, including intravenous immunoglobulin, plasmapheresis, and B-cell-targeted therapy with rituximab (5, 16). The gene discussed is GABBR1; the disease is stiff-person syndrome.